Barrow Receives DoD Grant to Repurpose Existing Drug for ALS

The United States Department of Defense (DoD) has awarded Barrow Neurological Institute an $840,000 grant to repurpose an existing class of drugs to target a specific molecular pathway that scientists have recently linked to ALS and other neurodegenerative diseases.

The two-year Therapeutic Idea Award—led by David Medina, PhD, an assistant professor in the Bowser Laboratory in the Department of Translational Neuroscience at Barrow—aims to increase our understanding of the role of m6A dysregulation in ALS and determine whether targeting this dysregulation with small-molecule drugs can reduce progression of the disease. 

Continue reading→

AZBioPEERS: How to Access Small Business Grants & Commercialization Resources at the National Cancer Institute

Are you developing a promising cancer-focused technology and seeking funding to advance it toward commercialization? Join the National Cancer Institute’s Small Business Innovation Research Development Center for an informational webinar on how early-stage companies, academic spinouts, and entrepreneurial researchers can access funding and commercialization support from the National Cancer Institute (NCI). Continue reading→

BD Names Bridget Bagnato Worldwide President of Peripheral Intervention

FRANKLIN LAKES, N.J., Nov. 4, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Bridget Bagnato has been appointed worldwide president of its Peripheral Intervention business unit, effective November 16.

Based at Peripheral Intervention’s headquarters in Tempe, Arizona, Bagnato will be responsible for driving the business unit’s global strategic, operational and commercial performance. She will report to Peter Menziuso, executive vice president and president of the Interventional segment.Continue reading→